Mysterious molecular phenomenon could boost precision of targeted drug delivery

October 06, 2020

A growing area of medicine looks at how cellular binding observed in nature - where molecules like viruses or proteins bind to specific receptors on a cell - can be mimicked to aid drug delivery.

Those developing targeted drug therapies aim to recreate this precise binding to develop nano-sized drug carriers that attach only to diseased cells. Once attached, these carriers would release their therapeutic load without affecting healthy cells. If drugs can be specifically targeted in this way, treatments would cause far fewer side effects.

One way to identify which cells are diseased is the number of receptors they express. Cancer cells, for example, tend to express more certain types of receptor than healthy cells.

Now, in a multi-centre collaboration led by Imperial and UCL, involving Beijing University of Chemical Technology, the Institute of Physics in Beijing and the Institute for Bioengineering of Catalonia, researchers have demonstrated how a mysterious molecular concept that the authors dubbed 'range selectivity' could be used to target diseased cells with high specificity. Range selectivity, until now a mysterious phenomenon, is where molecules called ligands attach only to cells whose receptors reach a certain number.

Senior author and principal investigator Dr Stefano Angioletti-Uberti, of Imperial's Department of Materials, said: "I came across the concept of range selectivity completely by accident. During my theoretical investigation of receptor-ligand binding I noticed that ligands weren't attaching above a certain threshold of receptor density and had my team re-check our code before realising it wasn't a bug."

In nature, range selectivity happens because of a balance of attractive and repulsive forces at the molecular level. Past a certain threshold the repulsive force must outweigh the attractive, and so binding is far less likely to take place. This is due to certain physical properties of ligand-receptor interactions.

Following their realisation, the group at Imperial used statistical mechanical modelling to show how modifying certain parameters could tune the balance of attractive and repulsive forces. This provided a 'molecular handle' to tune the upper and lower limit of the selectivity range. Their colleagues at UCL, led by Professor Giuseppe Battaglia, then confirmed these theoretical predictions using experimental data.

Researchers found they could tune the force balance using a 'molecular handle'

Dr Angioletti-Uberti added: "The key to unlocking highly targeted drug therapies could lie in directing drug carriers towards cells with a precise number of receptors.

"If we can find out which receptor densities are specific to different diseases and apply what we've demonstrated to drug carriers, we could treat those diseases effectively with fewer side effects."

Alongside drug targeting, the researchers say their work offers an important insight that could change the way future studies in this field are conducted. For example, researchers could now take into account that simply increasing the number of receptors does not necessarily increase the probability of binding, and in fact may cause it to significantly decrease.

It also offers clues that could go some way to explain why tumours evade attack from the immune system.

Dr Angioletti-Uberti said: "Could it be that tumour cells' receptor densities fall outside the range toward which immune cells are programmed to target?"

The authors are now looking into how to optimise receptor density on cells to ensure maximum binding, as many parameters like receptor and ligand type can affect the strength of these bonds.

Dr Angioletti-Uberti added: "Nature might already be using this form of binding to its own advantage, or indeed our disadvantage. Understanding this fully could lead to a wealth of disease-targeting possibilities."
-end-


Imperial College London

Related Diseases Articles from Brightsurf:

Understanding the spread of infectious diseases
Physicists at M√ľnster University (Germany) have shown in model simulations that the COVID-19 infection rates decrease significantly through social distancing.

Parkinson's disease is not one, but two diseases
Researchers around the world have been puzzled by the different symptoms and varied disease pathways of Parkinson's patients.

New gene implicated in neuron diseases
Healthy NEMF helps the cell recycle garbled protein fragments. But several mutant forms resulted in neuromuscular, neurodegenerative or other ALS-like disease, the scientists found.

Stretching your legs may help prevent diseases such as heart diseases and diabetes
New research published today in The Journal of Physiology shows that 12 weeks of easy-to-administer passive stretching helps improve blood flow by making it easier for your arteries to dilate and decreasing their stiffness.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

How many rare diseases are there?
Dr. Tudor Oprea says a better method for classifying rare diseases will lead to improved patient care.

A vaccine against chronic inflammatory diseases
In animals, a vaccine modifying the composition and function of the gut microbiota provides protection against the onset of chronic inflammatory bowel diseases and certain metabolic disorders, such as diabetes and obesity.

Ants fight plant diseases
New research from Aarhus University shows that ants inhibit at least 14 different plant diseases.

New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.

What is known -- and not known -- about heart muscle diseases in children
Cardiomyopathies (heart muscle diseases) in children are the focus of a new scientific statement from the American Heart Association that provides insight into the diagnosis and treatment of the diseases as well as identifying future research priorities.

Read More: Diseases News and Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.